Tilray medical supports scientific study on fibromyalgia with positive outcomes: effectiveness of cannabinoids treatment in pain management and other fibromyalgia-associated symptoms

Lisbon, portugal, sept. 09, 2024 (globe newswire) -- tilray medical, a division of tilray brands, inc. (“tilray”) (nasdaq: tlry; tsx: tlry) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, today announced a new scientific publication supported by tilray medical titled, treatment in pain management and other fibromyalgia-associated symptoms: a case series (tomas) .  the study examines the real-world impact of cannabinoid treatments on patients with fibromyalgia (fm) under the guidance of healthcare providers.
TLRY Ratings Summary
TLRY Quant Ranking